- Home
- ACHC vs LEGN Comparison
ACHC vs LEGN Comparison
Compare ACHC & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | LEGN |
|---|---|---|
| Founded | 2005 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 5.9B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHC | LEGN |
|---|---|---|
| Price | $14.93 | $21.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 13 |
| Target Price | $24.00 | ★ $69.58 |
| AVG Volume (30 Days) | ★ 2.7M | 2.5M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $3,265,548,000.00 | $909,045,000.00 |
| Revenue This Year | $6.50 | $68.52 |
| Revenue Next Year | $4.38 | $48.63 |
| P/E Ratio | $12.11 | ★ N/A |
| Revenue Growth | 4.58 | ★ 74.75 |
| 52 Week Low | $12.63 | $20.26 |
| 52 Week High | $47.08 | $45.30 |
Technical Indicators
Market Signals| Indicator | ACHC | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 47.34 | 31.83 |
| Support Level | $13.42 | $21.19 |
| Resistance Level | $14.74 | $22.07 |
| Average True Range (ATR) | 0.53 | 0.77 |
| MACD | 0.22 | 0.11 |
| Stochastic Oscillator | 93.91 | 25.71 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.